Surgical and Ablative Procedures for Venous Insufficiency and Varicose Veins

Policy Number: 2022T0447GG
Effective Date: June 1, 2022

Coverage Rationale

Varicose Vein Ablative and Stripping Procedures
The initial and subsequent radiofrequency ablation, endovenous laser ablation, Stripping, Ligation and excision of the Great Saphenous Vein (GSV) and Small Saphenous Veins (SSV) are considered reconstructive, proven and medically necessary when all of the following criteria are present:

- **Junctional Reflux:**
  - Ablative therapy for the GSV or SSV only if Junctional Reflux is demonstrated in these veins; or
  - Ablative therapy for Accessory Veins only if anatomically related persistent Junctional Reflux is demonstrated after the GSV or SSV have been removed or ablated.

- **Individual must have one of the following Functional or Physical Impairments:**
  - Skin ulceration; or
  - Documented episode(s) of frank bleeding of the Varicose Vein due to erosion of/or trauma to the skin; or
  - Documented Superficial Thrombophlebitis; or
  - Documented Venous Stasis Dermatitis causing Functional or Physical Impairment; or
  - Moderate to Severe Pain causing Functional or Physical Impairment.

- **Venous Size:**
  - The GSV must be 5.5 mm or greater when measured at the proximal thigh immediately below the saphenofemoral junction via Duplex Ultrasonography. (Navarro et al. 2002)
  - The SSV or Accessory Veins must measure 5 mm or greater in diameter immediately below the appropriate junction.

- **Duration of reflux, in the standing or reverse Trendelenburg position that meets the following parameters:**
  - Greater than or equal to 500 milliseconds (ms) for the GSV, SSV or principal tributaries.
  - Perforating veins > 350 ms.
  - Some Duplex Ultrasound readings will describe this as moderate to severe reflux which will be acceptable.
See Coding Clarification section. Adherence to American Medical Association (AMA) coding guidance is required when requesting coverage of endovenous ablation procedures. Note that only one primary code may be requested for the initial vein treated, and only one add-on code per extremity may be requested for any subsequent vein(s) treated.

Ablation of perforator veins is considered reconstructive, proven and medically necessary when the following criteria are present:
- Evidence of perforator Venous Insufficiency measured by recent Duplex Ultrasonography report (see criteria above); and
- Perforator vein size is 3.5 mm or greater; and
- Perforating vein lies beneath a healed or active venous stasis ulcer.

Endovenous mechnochemical ablation (MOCA) of Varicose Veins is unproven and not medically necessary due to insufficient evidence of efficacy.

**Ligation Procedures**
The following procedure is proven and medically necessary:
- Ligation at the saphenofemoral junction, as a stand-alone procedure, when used to prevent the propagation of an active clot to the deep venous system in individuals with ascending Superficial Thrombophlebitis who fail or are intolerant of anticoagulation therapy.

The following procedure is proven and medically necessary in certain circumstances:
- Ligation, subfascial, endoscopic surgery for treatment of perforating veins associated with chronic Venous Insufficiency. For medical necessity clinical coverage criteria, refer to the InterQual® CP: Procedures, Ligation, Subfascial, Endoscopic, Perforating Vein.

Click here to view the InterQual® criteria.

The following procedures are unproven and not medically necessary for treating Venous Reflux due to insufficient evidence of efficacy:
- Ligation of the GSV at the saphenofemoral junction, as a stand-alone procedure
- Ligation of the SSV at the saphenopopliteal junction, as a stand-alone procedure
- Ligation at the saphenofemoral junction, as an adjunct to radiofrequency ablation or endovenous laser ablation of the main saphenous veins.

**Ambulatory Phlebectomy**
Ambulatory phlebectomy for treating varicose veins is proven and medically necessary in certain circumstances. For medical necessity clinical coverage criteria, refer to the InterQual® CP: Procedures, Ambulatory Phlebectomy, Varicose Vein for:
- Hook Phlebectomy
- Microphlebectomy
- Mini Phlebectomy
- Stab Avulsion
- Stab Phlebectomy

Click here to view the InterQual® criteria.

**Other Procedures**
The following procedures are unproven and not medically necessary for treating Venous Reflux due to insufficient evidence of efficacy:
- Endovascular embolization of Varicose Veins using cyanoacrylate-based adhesive
- Endovenous low-nitrogen foam sclerotherapy of incompetent GSV, lesser saphenous veins, and accessory saphenous veins.
Documentation Requirements

Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The documentation requirements outlined below are used to assess whether the member meets the clinical criteria for coverage but do not guarantee coverage of the service requested.

<table>
<thead>
<tr>
<th>CPT Codes*</th>
<th>Required Clinical Information</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Surgical and Ablative Procedures for Venous Insufficiency and Varicose Veins</strong></td>
<td></td>
</tr>
<tr>
<td>36473</td>
<td>Medical notes documenting the following, when applicable:</td>
</tr>
<tr>
<td>36474</td>
<td>- Diagnosis</td>
</tr>
<tr>
<td>36475</td>
<td>- History of the medical condition(s) requiring treatment or surgical intervention</td>
</tr>
<tr>
<td>36476</td>
<td>- Documentation of signs and symptoms; including onset, duration, frequency, and which extremity (right, left, or both)</td>
</tr>
<tr>
<td>36478</td>
<td>- Relevant medical history, including:</td>
</tr>
<tr>
<td>36479</td>
<td>- DVT (deep vein thrombosis)</td>
</tr>
<tr>
<td>37700</td>
<td>- Aneurysm</td>
</tr>
<tr>
<td>37718</td>
<td>- Tortuosity</td>
</tr>
<tr>
<td>37722</td>
<td>- Physical exam, including:</td>
</tr>
<tr>
<td>37780</td>
<td>- Which extremity (right, left, or both)</td>
</tr>
<tr>
<td></td>
<td>- Vein(s) that will be treated [e.g., great saphenous vein (GSV) and small saphenous vein (SSV), etc.]</td>
</tr>
<tr>
<td></td>
<td>- Vein diameter including the specific anatomic location where the measurement was taken (e.g., proximal thigh, proximal calf, etc.)</td>
</tr>
<tr>
<td></td>
<td>- Duration of reflux including the position of member at the time of measurement and the anatomic location where the measurement was taken [e.g., standing, saphenofemoral junction (SFJ)]</td>
</tr>
<tr>
<td></td>
<td>- Pain or other symptoms that interfere with activities of daily living related to vein disease</td>
</tr>
<tr>
<td></td>
<td>- Functional disability(ies), as documented on a validated functional disability scale, interfering with the ability to stand or sit for long periods of time (preparing meals, performing work functions, driving, walking, etc.)</td>
</tr>
<tr>
<td></td>
<td>- Diagnostic study/imaging reports</td>
</tr>
<tr>
<td></td>
<td>- Pulses</td>
</tr>
<tr>
<td></td>
<td>- Prior conservative treatments tried, failed, or contraindicated. Include the dates and reason for discontinuation</td>
</tr>
<tr>
<td></td>
<td>- Proposed treatment plan with procedure code, including specific vein(s) that will be treated [e.g., great saphenous vein (GSV) and small saphenous vein (SSV), etc.], which extremity (left, right, or both), and date of procedure for each vein to be treated</td>
</tr>
</tbody>
</table>

In addition to the above, additional documentation requirements may apply for the following codes. Review the below listed policies in conjunction with the guidelines in this document. For CPT codes 37761 and 37785, refer to the Utilization Review Guideline titled [Outpatient Surgical Procedures – Site of Service](#).

*For code descriptions, refer to the [Applicable Codes](#) section.

Definitions

When applicable, refer to the member specific benefit plan document for definitions.

**Accessory/Tributary Vein:** Axial accessory or tributary saphenous veins indicate any venous segment ascending parallel to the Great Saphenous Vein and located more superficially above the saphenous fascia, both in the leg and in the thigh. These can include the anterior Accessory Vein, the postero-medial vein, circumflex veins (anterior or posterior), intersaphenous veins, Giacomini vein or posterior (Leonardo) or anterior arch veins.
Congenital Anomaly: A physical developmental defect that is present at the time of birth, and that is identified within the first twelve months of birth.

Congenital Anomaly (California only): A physical developmental defect that is present at the time of birth, and that is identified within the first twelve months of birth.

Cosmetic Procedures: Cosmetic Procedures are excluded from coverage. Procedures or services that change or improve appearance without significantly improving physiological function.

Cosmetic Procedures (California only): Procedures or services that are performed to alter or reshape normal structures of the body in order to improve appearance.

Duplex Ultrasonography: Combines a real-time B mode scanner with built-in Doppler capability. The B mode scanner outlines anatomical structure while Doppler detects the flow, direction of flow and flow velocity.

Endovenous Ablation: A minimally invasive procedure that uses heat generated by radiofrequency (RF) or laser energy to seal off damaged veins.

Functional or Physical Impairment: A physical or functional or physiological impairment causes deviation from the normal function of a tissue or organ. This results in a significantly limited, impaired, or delayed capacity to move, coordinate actions, or perform physical activities and is exhibited by difficulties in one or more of the following areas: physical and motor tasks; independent movement; performing basic life functions.

Great Saphenous Vein (GSV): The GSV originates from the dorsal arch of the foot and progresses medially and proximally along the distal extremity to join the common femoral vein.

Junctional Reflux: Reflux that exceeds a duration of 0.5 seconds at either:
- The saphenofemoral junction (SFJ) – Confluence of the Great Saphenous Vein and the femoral vein; or
- The saphenopopliteal junction (SPJ) – Confluence of the Small Saphenous Vein and the popliteal vein.

Ligation: Tying off a vein.

Moderate to Severe Pain: The Venous Clinical Severity Score (VCSS) describes moderate pain to be daily pain or other discomfort interfering with, but not preventing regular daily activities, and severe pain to be daily pain or discomfort that limits most regular daily activities (Vasquez et al. [American Venous Forum], 2010).

Reconstructive Procedures: Reconstructive procedures when the primary purpose of the procedure is either of the following:
- Treatment of a medical condition.
- Improvement or restoration of physiologic function.

Reconstructive procedures include surgery or other procedures which are related to an Injury, Sickness or Congenital Anomaly. The primary result of the procedure is not a changed or improved physical appearance.

Procedures that correct an anatomical Congenital Anomaly without improving or restoring physiologic function are considered Cosmetic Procedures. The fact that you may suffer psychological consequences or socially avoidant behavior as a result of an Injury, Sickness or Congenital Anomaly does not classify surgery (or other procedures done to relieve such consequences or behavior) as a reconstructive procedure.

Reconstructive Procedures (California only): Reconstructive procedure is covered to correct or repair abnormal structures of the body caused by congenital defects, developmental abnormalities, trauma, infection, tumors or disease. It includes medically necessary dental or orthodontic services that are an integral part of the reconstructive surgery for cleft palate procedures. Cleft palate means a condition that may include a cleft palate, cleft lip, or other craniofacial anomalies related with a cleft palate. The purpose of reconstructive procedure is to correct abnormal structures of the body to improve function or create a normal appearance to the extent possible.
Reticular Vein: Reticular Veins are dilated dermal veins less than 4mm in diameter that communicate with either or both Telangiectasia and saphenous tributaries.

Sickness: Physical illness, disease or pregnancy. The term Sickness includes mental illness or substance-related and addictive disorders, regardless of the cause or origin of the mental illness or substance-related and addictive disorder.

Sickness (California only): Physical illness, disease or pregnancy. The term Sickness includes mental illness or substance-related and addictive disorders, regardless of the cause or origin of the mental illness or substance-related and addictive disorder.

Small Saphenous Vein: Superficial vein of the calf.

Spider Vein: Spider Veins/Telangiectasia are the permanent dilation of preexisting small blood vessels, generally up to 1mm in size.

Stripping: Surgical removal of superficial veins.

Superficial Thrombophlebitis: Inflammation of a vein due to a blood clot in a vein just below the skin’s surface.

Telangiectasia: See Spider Vein.

Varicose Veins: Abnormally enlarged veins that are frequently visible under the surface of the skin; often appear blue, bulging and twisted.

Venous Reflux/Insufficiency: Venous Reflux is reversed blood flow in the veins (away from the heart). Abnormal (pathological reflux) is defined as reverse flow that lasts beyond a specified period of time as measured by Doppler ultrasound. Normal (physiological reflux) is defined as reverse flow that lasts less than a specified period of time as measured by Doppler ultrasound. Abnormal (pathological reflux) times exceed different thresholds depending on the system of veins:
- Deep veins: 1 sec
- Superficial veins: 0.5 sec
- Perforator veins: 0.35 sec

Venous Stasis Dermatitis: A skin inflammation due to the chronic buildup of fluid (swelling) under the skin.

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

Coding Clarifications:
- According to the American Medical Association (AMA), CPT code 37241 is specific to venous embolization/occlusion and excludes lower extremity venous incompetency. Coding instructions state that 37241 should not be used to request treatment of incompetent extremity veins. For sclerosis of veins or endovenous ablation of incompetent extremity veins, see 36468-36479 (CPT Assistant, 2014).
- Adherence to AMA coding guidance is required when requesting endovenous ablation procedures.

Per AMA coding guidance, the initial incompetent vein treated (e.g., 36475) may only be requested once per extremity. For endovenous ablation, treatment of subsequent incompetent veins in the same extremity as the initial vein treated (e.g., 36476), only one add-on code per extremity may be requested, regardless of the number of additional vein(s) treated (CPT Assistant, November 2016).
Therefore, only one primary code may be requested for the initial vein treated, and only one add-on code per extremity may be requested for any subsequent vein(s) treated.

<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>36465</td>
<td>Injection of non-compounded foam sclerosant with ultrasound compression maneuvers to guide dispersion of the injectate, inclusive of all imaging guidance and monitoring; single incompetent extremity truncal vein (e.g., great saphenous vein, accessory saphenous vein)</td>
</tr>
<tr>
<td>36466</td>
<td>Injection of non-compounded foam sclerosant with ultrasound compression maneuvers to guide dispersion of the injectate, inclusive of all imaging guidance and monitoring; multiple incompetent truncal veins (e.g., great saphenous vein, accessory saphenous vein), same leg</td>
</tr>
<tr>
<td>36473</td>
<td>Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, mechanoochemical; first vein treated</td>
</tr>
<tr>
<td>36474</td>
<td>Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, mechanoochemical; subsequent vein(s) treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>36475</td>
<td>Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, radiofrequency; first vein treated</td>
</tr>
<tr>
<td>36476</td>
<td>Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, radiofrequency; subsequent vein(s) treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>36478</td>
<td>Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, laser; first vein treated</td>
</tr>
<tr>
<td>36479</td>
<td>Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, laser; subsequent vein(s) treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>36482</td>
<td>Endovenous ablation therapy of incompetent vein, extremity, by transcatheter delivery of a chemical adhesive (e.g., cyanoacrylate) remote from the access site, inclusive of all imaging guidance and monitoring, percutaneous; first vein treated</td>
</tr>
<tr>
<td>36483</td>
<td>Endovenous ablation therapy of incompetent vein, extremity, by transcatheter delivery of a chemical adhesive (e.g., cyanoacrylate) remote from the access site, inclusive of all imaging guidance and monitoring, percutaneous; subsequent vein(s) treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>37500</td>
<td>Vascular endoscopy, surgical, with ligation of perforator veins, subfascial (SEPS)</td>
</tr>
<tr>
<td>37700</td>
<td>Ligation and division of long saphenous vein at saphenofemoral junction, or distal interruptions</td>
</tr>
<tr>
<td>37718</td>
<td>Ligation, division, and stripping, short saphenous vein</td>
</tr>
<tr>
<td>37722</td>
<td>Ligation, division, and stripping, long (greater) saphenous veins from saphenofemoral junction to knee or below</td>
</tr>
<tr>
<td>37735</td>
<td>Ligation and division and complete stripping of long or short saphenous veins with radical excision of ulcer and skin graft and/or interruption of communicating veins of lower leg, with excision of deep fascia</td>
</tr>
<tr>
<td>37760</td>
<td>Ligation of perforator veins, subfascial, radical (Linton type), including skin graft, when performed, open, 1 leg</td>
</tr>
<tr>
<td>37761</td>
<td>Ligation of perforator vein(s), subfascial, open, including ultrasound guidance, when performed, 1 leg</td>
</tr>
<tr>
<td>37765</td>
<td>Stab phlebectomy of varicose veins, one extremity; 10-20 stab incisions</td>
</tr>
<tr>
<td>37766</td>
<td>Stab phlebectomy of varicose veins, one extremity; more than 20 incisions</td>
</tr>
<tr>
<td>37780</td>
<td>Ligation and division of short saphenous vein at saphenopopliteal junction (separate procedure)</td>
</tr>
<tr>
<td>37785</td>
<td>Ligation, division, and/or excision of varicose vein cluster(s), one leg</td>
</tr>
<tr>
<td>37799</td>
<td>Unlisted procedure, vascular surgery</td>
</tr>
</tbody>
</table>

CPT® is a registered trademark of the American Medical Association
Description of Services

Varicose Veins are enlarged veins that are swollen and raised above the surface of the skin. They can be dark purple or blue, and look twisted and bulging. Varicose Veins are commonly found on the backs of the calves or on the inside of the leg. Veins have one-way valves that help keep blood flowing towards the heart. When the valves become weak or damaged and do not close properly, blood can back up and pool in the veins causing them to get larger. The resulting condition is known as Venous Insufficiency or Venous Reflux. Varicose Veins may lead to complications such as pain, blood clots or skin ulcers.

Duplex ultrasound is considered the gold standard for diagnosis of superficial venous incompetence. The CEAP (clinical, etiology, anatomy, pathophysiology) classification system is used to describe the degree of varicosity. The “C” part of CEAP classification is more useful and practical in rating the severity of Varicose Veins:

- C0: No visible or palpable signs of venous disease
- C1: Telangiectasis (Spider Veins) or Reticular Veins
- C2: Varicose Veins (diameter of vein is > 3mm)
- C3: Edema
- C4a: Pigmentation and eczema
- C4b: Lipodermatosclerosis and atrophie blanche
- C5: Healed venous ulcer
- C6: Active venous ulcer

(American Venous Forum [AVF], 2004)

Venous clinical severity scoring has been used to measure clinical improvement after treatment of varicose veins. Other venous severity scoring methods include Venous Severity Score, Venous Clinical Severity Score, Venous Segmental Disease Score (AVF, 2018).

Preoperative venous duplex ultrasound is used to evaluate patients for venous insufficiency symptoms or suspected DVT; it can provide a road map of vein anatomy similar to contrast venography, as well as essential hemodynamic information about the presence of proximal obstruction, vein valve function, and venous reflux (Lin et al., 2015).

Varicose Veins are treated with lifestyle changes and medical procedures done either to remove the veins or to close them. Endovenous Ablation therapy uses lasers or radiofrequency energy to create heat to close off a Varicose Vein. Vein Stripping and Ligation involves tying shut and removing the veins through small cuts in the skin (National Heart, Lung and Blood Institute [NHLBI], 2014).

Endomechanical ablation uses a specialized, rotating catheter (e.g., ClariVein) to close off a Varicose Vein by damaging the vessel lining prior to injecting a sclerosing agent. This technique is also referred to as mechanochemical ablation (MOCA), mechanicochemical endovenous ablation (MCEA) and mechanically enhanced endovenous chemical ablation (MEECA).

Endovascular embolization using cyanoacrylate-based adhesive (e.g., VenaSeal™ Closure System) is a minimally invasive, non-thermal and non-sclerosant procedure that does not require tumescent anesthesia. The medical adhesive is used to close the lower extremity superficial truncal veins, such as the Great Saphenous Vein, in individuals with symptomatic Venous Reflux disease.

Endovascular embolization using endovenous foam sclerotherapy with polidocanol endovenous microfoam (PEM) (e.g., Varithena™ [Provensis Ltd.]) is a prescribed proprietary cannister that generates a sterile, uniform, stable, low-nitrogen polidocanol 1% microfoam sclerosant intended for ultrasound-guided intravenous (IV) injection for treating venous incompetence and varicosities (Hayes, 2020). The aim of ultrasound-guided foam sclerotherapy for Varicose Veins is to damage the endothelial surface of the vein causing scarring and leading to blockage of the treated Varicose Veins. Sclerosant, in the form of a foam, is intended to have good surface area contact with the vein walls (National Institute of Health and Care Excellence [NICE], 2013).
Clinical Evidence

In a meta-analysis, Hamann et al. (2017) compared the long-term efficacy of different treatment modalities for varicose veins: high ligation with stripping (HL+S), endovenous thermal ablation (EVTA), mainly consisting of endovenous laser ablation (EVLA) or radiofrequency ablation (RFA), and ultrasound guided foam sclerotherapy (UGFS)). Three randomized controlled trials (RCTs) and 10 follow-up studies of RCTs with follow-up ≥ 5 years were included. In total, 611 legs were treated with EVLA, 549 with HL+S, 121 with UGFS, and 114 with HL+EVLA. UGFS had significantly lower pooled anatomical success rates than HL+S, EVLA, and EVLA with high ligation: 34% (95% CI 26-44) versus 83% (95% CI 72-90), 88% (95% CI 82-92), and 88% (95% CI 17-100) respectively; p ≤ .001. The pooled recurrent reflux rate at the saphenofemoral junction (SFJ) was significantly lower for HL+S than UGFS (12%, 95% CI 7-20, vs. 29%, 95% CI 21-38; p ≤ .001) and EVLA (12%, 95% CI 7-20, vs. 22%, 95% CI 14-32; p = .038). - Venous Clinical Severity Score (VCSS) were pooled for EVLA and HL+S, which showed similar improvements. Based on the results of the meta-analysis, EVLA and HL+S show higher success rates than UGFS 5 years after greater saphenous vein (GSV) treatment. Recurrent reflux rates at the SFJ were significantly lower in HL+S than UGFS and EVLA. VCSS scores were similar between EVLA and HL+S. Rass et al. (2015), Gauw et al. (2016), and Flessenkämper et al. (2016), which were previously cited in this policy, are included in the Hamann et al. (2017) meta-analysis.

Boersma et al. (2016) performed a systematic review and meta-analysis of treatment modalities for small saphenous vein (SSV) insufficiency. The review included 49 studies (5 RCTs, 44 cohort studies) reporting on the different treatment modalities: surgery (n=9), EVLA (n=28), RFA (n=9), UGFS (n=6) and MOCA (n=1). The primary outcome of anatomical success was defined as closure of the treated vein on follow-up duplex ultrasound imaging. Secondary outcomes were technical success and major complications. The pooled anatomical success rate was 58.0% for surgery in 798 veins, 98.5% for EVLA in 2950 veins, 97.1% for RFA in 386 veins and 63.6% for UGFS in 494 veins. One study reported results of MOCA, with an anatomical success rate of 94%. Neurologic complications were most frequently reported after surgery and thermal ablation. Deep venous thrombosis was a rare complication. The authors concluded that EVLA and RFA are preferred to surgery and foam sclerotherapy in the treatment of SSV insufficiency. Although data on nonthermal techniques is still sparse, the potential benefits, especially the reduced risk of nerve injury, might be of considerable clinical importance. Theivacumar et al. (2007) and O’Hare et al. (2008), which were previously cited in this policy, are included in the Hamann et al. (2017) meta-analysis.

Go et al. (2016) reviewed the cases of 24 limbs of 17 patients who underwent EVLA between 2004 and 2007 that were examined with duplex ultrasonographic scans at a mean follow-up of 66 months. There were five recurrences of SFJ reflux. The occlusion rate was 79.2% at a mean follow-up of 66.1 months. There were 14 recanalization’s and 5 recurrences of the GSV. Five partial and nine total recanalization’s were observed. The authors concluded that EVLA is an effective and minimally invasive treatment for varicose veins and although their long-term result was acceptable, the result was not outstanding. A study limitation was the small patient population and lack of comparison group.

In a systematic review and meta-analysis of RCTs of endovenous ablation (EVA) of the GSV, O’Donnell et al. (2016) evaluated recurrence and cause of varicose veins after surgery (REVAS). Seven RCTs provided eight comparisons (one study compared both types of EVA to a comparator arm): three used RFA, and five employed EVLA. Overall recurrent varicose veins developed in 125 limbs after EVA (22%), with no difference in the incidence vs the ligation and stripping (L&S) group (22%) based on the number of limbs available at the time of the development of recurrence for both groups, but this incidence is dependent on the length of follow-up after the initial treatment. Neovascularization occurred in only two limbs (2%) after EVA vs 18 (18%) in the

Coverage Limitations and Exclusions

The following procedures are excluded from coverage:

- Procedures that correct an anatomical Congenital Anomaly without improving or restoring physiologic function are considered Cosmetic Procedures and therefore excluded from coverage. The fact that a Covered Person may suffer psychological consequences or socially avoidant behavior as a result of an Injury, Sickness or Congenital Anomaly does not classify surgery (or other procedures done to relieve such consequences or behavior) as a reconstructive procedure.
- Any procedure that does not meet the criteria in the Coverage Rationale section.
- Treatments for Spider Veins and/or Telangiectasias are considered to be cosmetic and therefore excluded from coverage.
- Endovenous Ablation (radiofrequency and/or laser) of either reticular or telangiectatic veins is not reconstructive and not medically necessary and therefore excluded from coverage.
L&S group. Recanalization was the most common cause of REVAS for EVA (32%; 40 of 125 limbs), followed by the development of anterior accessory saphenous vein incompetence (19%; 23 of 125 limbs). The authors concluded that there is no difference in the incidence of REVAS for EVA vs L&S, but the causes of REVAS are different with L&S.

In a systematic review and meta-analysis to compare traditional surgery and EVLA for the treatment of venous insufficiency of the GSVs, Quarto et al. (2016) evaluated 756 legs treated with a conventional surgical procedure and 755 legs treated with EVLA. Only RCTs based at least on 6 months follow-up were considered eligible in the study. The authors did not find a statistically significant difference in the presence or absence of reflux between the two techniques, and noted that although EVLA did not prove to be superior in terms of recurrence to the surgical technique, EVLA remains a viable treatment option in patients with impaired GSV, reducing postoperative pain and hospital stay.

Woźniak et al. (2016) conducted a cohort study of complications and failure of EVLA and RFA in a 5-year follow-up. One hundred ten adult participants with varicose veins clinical grade C2 to C6, treated for isolated GSV or SSV insufficiency in a single lower extremity in 2009 to 2010, were enrolled and subdivided into EVLA (n=56) and RFA (n=54) groups. Both groups were compared for demography, disease stage, affected veins, perioperative, and postoperative complications as well as treatment efficacy. The perioperative and postoperative complications were statistically insignificant. Treatment efficacy, expressed as the number of participants with recurrent varicosity and recanalization, was comparable in both groups. The clinically significant recanalization rate was 3.6% and 5.6% in EVLA and RFA groups, respectively. The authors concluded that EVLA and RFA for the management of lower extremity varicose vein offer comparable efficacy and safety in a 5-year follow-up. The findings are however limited by lack of randomization and a sample size that might have been too small to detect clinically significant differences between the two procedures.

Chaar et al. (2011) conducted a retrospective cohort analysis of patients undergoing endovenous laser therapy on the GSV, SSV, or anterior accessory veins (AAV). A total of 732 ablations were reviewed, involving 175 men and 557 women. Veins that measured <1 cm in diameter were considered small, whereas those that measured ≥1 cm at any point were considered to be large. Average follow-up with duplex ultrasound was 3 weeks, and all patients underwent at least one postprocedural ultrasound. In all, 565 (77.3%) GSVs, 113 (15.5%) SSVs, and 53 (7.3%) AAVs were treated. A total of 88 ablations were performed on veins measuring ≥ 1 cm, 12% of all treated veins. In all, 82 GSVs, three SSVs, and three AAVs measured >1 cm, and GSVs comprised 93.2% of treated large veins (p ≤ 0.001 vs. entire cohort). Based on the results, complication rates and closure rates are not significantly different for veins of diameter ≥ 1 cm and smaller veins. Although more energy is used, the authors observed that this has not translated into higher complication rates, thus in their opinion making EVLT safe and effective for large vein closure. Significantly higher failure and complication rates were seen in SSV and AAV treatment as compared with GSV treatment.

Theivacumar et al. (2011) conducted a cohort study to assess the effectiveness and safety of EVLA in the management of recurrent varicose veins (RVVS). One-hundred four limbs (95 patients) undergoing EVLA for RVVS were grouped according to pattern of reflux. For patients with recurrent SFJ/GSV (Group GR) and SPJ/SSV (Group SR) varicosities ablation rates and quality of life (QoL) using the Aberdeen Varicose Vein Severity Scores (AVVSS) were compared with those for age/sex matched patients undergoing EVLA for primary GSV/SSV dependent varicose veins (Groups GP and SP). In patients with RVVS the axial vein was ablated in 102/104 (98%) limbs while 2 GSVs (group GR) partially recanalized by 3 months (GSV ablated in 49/51 (96%) limbs versus 50/51 (98%) limbs in GP [p = 0.2]). Improvements in AVVSS at 3 months (median GR: 14.2 (inter-quartile range (IQR) 10.2-18.9) to 3.2(1.2-6.4), p < 0.001; GP: median 15.9(IQR 11.4-22.7) to 3.8(1.1-5.6), p < 0.001, Mann-Whitney u-test) were similar (78% versus 76%, p = 0.23). The SSV was ablated in 24/24 limbs in groups SR and SP and the % improvement in AVVSS was 83% (median 14.4 (IQR 8.2-19.4) to 2.4 (1.9-4.6), p < 0.001, Mann-Whitney u-test) and 84% (median 13.8 (IQR 6.3-17.5) to 2.2 (1.2-5.1), p < 0.001) respectively (p = 0.33). These improvements persisted at 1 year follow-up. A further 29 limbs with isolated anterior accessory great saphenous vein (AAGSV) or segmental GSV/SSV reflux were successfully ablated. Complication rates for primary and RVVS were similar. The authors concluded that EVLA is a safe and effective option for the treatment of RVVS and could be a preferred option for suitable patients.

Labropoulos et al. (2010) conducted a prospective study to determine the prevalence, distribution, and extent of varicosities and focal dilatations in the saphenous trunks, their association with the sites of reflux, and their correlation with CEAP classes. Color-flow duplex scan imaging was used to evaluate the entire venous system from groin to ankle for reflux and obstruction. Varicose segments and focal dilatations of the GSV and SSV were recorded, and the diameters throughout the length of the saphenous trunks were measured. The presence of varicosities in the tributaries and accessory veins were documented. The included 500 patients (681 limbs) were divided into two groups based on CEAP class: group A (C2 + C3) and group B (C4-6).
Group A had significantly more women than group B and a younger mean age (48 vs 56 years). Overall, GSV reflux (86%) was more prevalent than SSV reflux (17%), \( P < .0001 \). Saphenous trunk diameters, SFJ and saphenopopliteal junction (SPJ) involvement were greater in group B, \( P < .01 \). Group C had smaller saphenous diameters compared to group A in all locations \( P < .05 \) but the malleoli. The prevalence of the saphenous varicose segments in both groups was small with the GSV in group B being the highest (4.3%) and the SSV in group A being the smallest (1.2%). Focal dilatations were significantly more prevalent than varicosities in the saphenous trunks \( P < .0001 \). Varicosities of tributaries and accessory veins were more prevalent than those of saphenous trunks \( P < .0001 \). The mean length of varicose segments in the saphenous trunks was short (3.8 cm, range, 2.1-6.4 for group A vs 4.1 cm, range, 2.3-8.3 for group B, \( P = .09 \)). The authors concluded that focal dilatations are far more common than varicosities. Because both of these entities are more prevalent in the accessory saphenous veins and tributaries, and CEAP class correlates positively with the extent of reflux and saphenous trunk diameter, studies on earlier interventions are warranted to prevent CVD progression.

In a systematic review, Darwood and Gough (2009) found that adjunctive saphenofemoral ligation is not necessary to achieve success with endovenous laser therapy of the GSV. Similarly, a RCT conducted by Disselhoff et al. (2008) found that the addition of saphenofemoral ligation to endovenous ablation made no difference to the short-term outcome of varicose vein treatment. Long-term follow-up at 5 years found similar results (Disselhoff et al. 2011). Further studies with larger patient populations are needed to establish the superiority of adjunctive saphenofemoral ligation in improving long-term outcomes.

Theivacumar et al. (2009) compared 33 patients (21 women and 12 men) undergoing AAGSV EVLA alone (group A) and 33 age/sex-matched controls undergoing GSV EVLA (Group B) to assess assesses the short-term efficacy (abolition of reflux on Duplex ultrasound) of EVLA of the AAGSV with preservation of a competent GSV in the treatment of varicose veins occurring due to isolated AAGSV incompetence. Comparisons included ultrasound assessment of SFJ competence, successful axial vein ablation, Aberdeen Varicose Vein Symptom Severity Scores (AVVSS) and a visual analogue patient-satisfaction scale. At the 1-year follow-up, EVLA had successfully abolished the target vein reflux (AAGSV: median length 19 cm (inter-quartile range, IQR: 14-24 cm) vs. GSV: 32 cm (IQR 24-42 cm)) and had restored SFJ competence in all patients. Twenty of the 33 patients (61%) in group A and 14 of the 33 (42%) in group B (\( p=0.218 \)) required post-ablation sclerotherapy at 6 weeks post-procedure for residual varicosities. The AVVSS at 12 months follow-up had improved from the pre-treatment scores in both the groups (group A: median score 4.1 (IQR 2.1-5.2) vs. 11.6 (IQR: 6.9-15.1) \( p<0.001 \); group B: median score 3.3 (IQR 1.1-4.5) vs. 14.5 (IQR 7.6-20.2), \( p<0.001 \), with no significant difference between the groups. The authors concluded that AAGSV EVLA abolishes SFJ reflux, improves symptom scores and is, therefore, suitable for treating varicose veins associated with AAGSV reflux.

Theivacumar et al. (2008) conducted a randomized controlled trial to assess whether more extensive GSV ablation enhances resolution and influences symptom improvement in patients with previous above-knee (AK) GSV EVLA. Sixty-eight limbs (65 patients) with varicosities and above and below-knee GSV reflux were randomized to Group A: AK-EVLA (\( n = 23 \)); Group B: EVLA mid-calf to groin (\( n = 23 \)); and Group C: AK-EVLA, concomitant below-knee GSV foam sclerotherapy (\( n = 22 \)). Primary outcomes were residual varicosities requiring sclerotherapy (6 weeks), improvement in Aberdeen varicose vein severity scores (AVVSS, 12 weeks), patient satisfaction, and complication rates. EVLA ablated the treated GSV in all limbs. Sclerotherapy requirements were Group A: 14/23 (61%); Group B: 4/23 (17%); and Group C: 8/22 (36%); chi2 = 9.3 (2 df \( p = .01 \) with \( P(A-B) = 0.006 \); \( P(B-C) = 0.19 \); \( P(A-C) = 0.14 \). AVVSS scores improved in all groups as follows: A: 14.8 (9.3-22.6) to 6.4 (3.2-9.1), (\( P < .001 \)); B: 15.8 (10.2-24.5) to 2.5 (1.1-3.7), (\( P < .001 \)); and C: 15.1 (9.0-23.1) to 4.1 (2.3-6.8), (\( P < .001 \)) and \( P(A-B) = 0.011 \), \( P(A-C) = 0.042 \). Patient satisfaction was highest in Group B. BK-EVLA was not associated with saphenous nerve injury. The authors concluded that extended EVLA is safe, increases spontaneous resolution of varicosities, and has a greater impact on symptom reduction.

Marston et al. (2006) evaluated 89 limbs in 80 patients with CEAP clinical class 3-6 CVI and superficial venous reflux who were treated with saphenous ablation utilizing radiofrequency (RF) or endovenous laser treatment (EVLT). There were no significant differences in preoperative characteristics between the groups treated with RFA or EVLT. Patients were reexamined within 3 months of ablation with duplex to determine anatomic success of the procedure, and with repeat air plethysmography (APG) to determine the degree of hemodynamic improvement. Postoperatively, 86% of limbs demonstrated near total closure of the saphenous vein to within 5 cm of the SFJ. Eight percent remained open for 5-10 cm from the junction, and 6% demonstrated minimal or no saphenous ablation. The VFI improved significantly after ablation in both the RF and EVLT groups. Post ablation, 78% of the 89 limbs were normal, with a VFI <2 mL/second, and 17% were moderately abnormal, between 2 and 4 mL/second. VCSS scores (11.5 +/-4.5 pre-ablation) decreased significantly after ablation to 4.4 +/-2.3. The authors concluded that minimally invasive saphenous ablation, using either RFA or EVLT, corrects or significantly improved the hemodynamic abnormality and clinical symptoms associated with superficial venous reflux in more than 90% of cases.
Wichers et al. (2005) performed a systematic review of randomized trials evaluating the safety and efficacy of medical (antiocoagulants) or surgical (ligation or stripping of the affected veins) treatments of superficial vein thrombosis (SVT) for the prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). Five studies were included. Pooling of the data was not possible due to the heterogeneity among the studies. Three studies had major methodological drawbacks limiting the clinical applicability of the results. One of the remaining (pilot) studies showed a non-significant trend in favor of high-compared to low-dose unfractionated heparin for the prevention of venous thromboembolism (VTE). The last remaining study showed a non-significant trend in favor of short-term treatment with low-molecular-weight heparin (LMWH), or a non-steroidal anti-inflammatory drug (NSAID) as compared to placebo shortly after treatment with respect to VTE, but the apparent benefit disappeared after three months of follow-up. More RCTs are needed before any evidence-based recommendations on the treatment of SVT for the prevention of VTE can be given. With the lack of solid evidence, the authors suggest treating patients with at least intermediate doses of LMWH. Surgical treatment of SVT may be considered when varicose veins are involved.

Fifteen hundred consecutive patients were examined by Labropoulos et al. (2004) using duplex ultrasound (DU) to determine the patterns and clinical importance of SFJ reflux in patients with chronic venous disease (CVD) and a normal GSV trunk. Patients with reflux involving the SFJ and/or its tributaries only were included, and its prevalence and patterns were studied. Patients with GSV trunk reflux or in any other veins were excluded. The SFJ diameter was categorized as normal, dilated or varicose. The results of surgery were evaluated by DU in 42 patients 1 year after the procedure. SFJ area incompetence with a competent GSV trunk occurred in 8.8% of limbs. It was significantly more common in CEAP class 2, 13.6% compared to class 3, 8.2% (p=0.03), class 1, 2.7%, class 4, 4.4% and classes 5 and 6 together, 1.5% (p<0.001 for all). The SFJ had a normal diameter in 21%, dilated in 62% and varicose in 17%. Reflux was seen in 39% of limbs with a normal SFJ diameter, in 85% of those with a dilated SFJ and in all varicose SFJs. Of the 42 operated limbs, 27 had ligation and division of the SFJ and tributary phlebectomies. Fifteen had tributary phlebectomies only, leaving the SFJ intact. At one-year follow-up, SFJ area reflux was found in six limbs (14.3%), involving the SFJ alone in 1, a main tributary in 1 and 4 small tributaries. No reflux was found in the GSV trunk. All but two of the 42 patients were satisfied with the results. The authors observed that SFJ reflux with tributary involvement and sparing of the GSV trunk occurs in 8.8% of CVD patients. Such reflux is found in the entire spectrum of CVD, but it is more common in class 2. The authors concluded that local surgery with or without SFJ ligation has very good results at 1 year. In addition, they recommend that duplex ultrasound scanning prior to treatment is important in all patients so that the intact GSV can be spared.

In a literature review of long-term results following high ligation supplemented by sclerotherapy, Recek (2004) found that ligation of the SFJ alone provokes a higher recurrence rate in comparison with high ligation and stripping. The hemodynamic improvement achieved immediately after high ligation deteriorates progressively during the follow-up owing to recurrent reflux.

In 2004, Winterborn conducted an 11-year follow-up study to a randomized clinical trial (Jones, et al. 1996). The objective of the Jones et al. (1996) trial was to determine whether routine stripping of the long saphenous vein reduced recurrence after varicose vein surgery. Two years after the procedure, 81 patients (113 legs: 53 strip, 60 ligated) with a mean follow-up of 31-months (range 28-33 months) were reassessed with a satisfaction questionnaire, clinical exam and duplex scanning. Eighty-nine percent were satisfied with their results, although 35% had recurrent veins on clinical examination. Recurrence was reduced from 43% to 25% in patients who had their long saphenous vein stripped (p=0.04). Neovascularization (serpentine tributaries arising from the ligated SFJ) was detected in 52% of limbs and was the commonest cause of recurrence. Most tributaries were less than 3 mm in diameter and only caused recurrence if the long saphenous vein or a major thigh vein was intact. Twelve patients had tributaries greater than 3 mm diameter, and all had recurrent varicose veins. Winterborn et al. (2004) reported that a cumulative total of 83 legs had developed clinically recurrent varicose veins by 11 years (62%). There was no statistically significant difference between the ligation-only and the stripping groups. Reoperation was required for 20 of 69 legs that underwent ligation alone compared with 7 of 64 legs that had additional long saphenous vein stripping. Freedom from reoperation at 11 years was 70% after ligation, compared with 86% after stripping. The presence of neovascularization, an incompetent superficial vessel in the thigh or an incompetent SFJ on duplex imaging at 2 years postoperatively increased the risk of a patient's developing clinically recurrent veins. Results from the study indicate that stripping the long saphenous vein is recommended as part of routine varicose vein surgery as it reduces the risk of reoperation after 11 years, although it did not reduce the rate of visible recurrent veins.

Labropoulos et al. (2003) conducted a prospective study to determine the upper limits of normal for duration and maximum velocity of retrograde flow (RF) in lower extremity veins. Eighty limbs in 40 healthy subjects and 60 limbs in 45 patients with chronic venous disease were examined with duplex scanning in the standing and supine positions. Each limb was assessed for reflux at 16 venous sites, including the common femoral, deep femoral, and proximal and distal femoral veins; proximal and
distal popliteal veins; gastrocnemial vein; anterior and posterior tibial veins; peroneal vein; GSV, at the SFJ, thigh, upper calf, and lower calf; and lesser saphenous vein, at the SPJ and mid-calf. Perforator veins along the course of these veins were also assessed. In the healthy volunteers, 1553 vein segments were assessed, including 480 superficial vein segments, 800 deep vein segments, and 273 perforator vein segments; and in the patients, 1272 vein segments were assessed, including 360 superficial vein segments, 600 deep vein segments, and 312 perforator vein segments. Detection and measurement of reflux were performed at duplex scanning. Standard pneumatic cuff compression pressure was used to elicit reflux. Duration of RF and peak vein velocity were measured immediately after release of compression. Based on the results, the authors observed that the cutoff value for reflux in the superficial and deep calf veins is greater than 500 ms. However, in their opinion the reflux cutoff value for the femoropopliteal veins should be greater than 1000 ms. Outward flow in the perforating veins should be considered abnormal at greater than 350 ms. Reflux testing should be performed with the patient standing.

Proebstle et al. (2003) studied 85 consecutive patients with clinical stage C(2-6) E(P,S) A(S,P,D) P(R) disease to establish the incidence of early recanalization after endovenous laser treatment (ELT) and evaluate the histopathologic features of reperfused and excised GSV. Twelve months of follow-up with duplex scanning at regular intervals was possible in 104 treated veins (95.4%) in 82 patients (96.5%). Recanalized vessels were removed surgically and examined at histopathology. ELT-induced occlusion proved permanent at duplex scanning over 12 months of follow-up in 94 of 104 GSV (90.4%) in 73 patients. In 4 patients, 5 GSV (4.8%) were recanalized completely after 1 week, after 3 months (n = 3), or after 12 months. Another 5 GSV (4.8%) in 5 patients exhibited incomplete proximal recanalization over the 12 months of follow-up. Finally, 9 recanalized vessels (8.6%) required further treatment with high ligation and stripping. The authors concluded that early recanalization requiring retreatment is observed in less than 10% of GSV after ELT. The histopathologic pattern mimics recanalization after thrombophlebitic occlusion.

In a cohort study, Navarro et al. (2002) evaluated the clinical significance of GSV diameter determined in the thigh and calf as a marker of global hemodynamic impairment and clinical severity in a model comprising patients with SFJ and truncal GSV incompetence. Eighty-five consecutive patients, aged 28 to 82 (mean, 46.2) years, 112 lower limbs with SFJ and truncal GSV incompetence were investigated. The GSV diameter was measured on standing at the knee, and at 10, 20, and 30 cm above and below the knee, and in the thigh and calf, respectively, using B-mode imaging. The venous filling index (VFI), venous volume (VV), and residual volume fraction (RVF) were measured by air plethysmography. The GSV diameter at all 7 limb levels studied correlated well with VV (except at the distal calf), VFI, RVF, and CEAP (P< or =.009 for all). A GSV diameter of 5.5 mm or less predicted the absence of abnormal reflux, with a sensitivity of 78%, a specificity of 87%, positive and negative predictive values of 78%, and an accuracy of 82%. A GSV diameter of 7.3 mm or greater predicted critical reflux (VFI >7 mL/s), with an 80% sensitivity, an 85% specificity, and an 84% accuracy. In the authors’ opinion, GSV diameter proved to be a relatively accurate measure of hemodynamic impairment and clinical severity in a model of SFJ and GSV incompetence, predicting not only the absence of abnormal reflux, but also the presence of critical venous incompetence, assisting in clinical decision making before considering greater saphenectomy.

Sullivan et al. (2001) performed a systematic review of the literature evaluating surgical and medical management of above-knee superficial thrombophlebitis (AK-STP) not involving the deep venous system. Six studies were included for a total of 246 patients in the surgical arm and 88 patients in the medical arm. Surgical treatment modalities halt the progression of thrombus into the deep venous system through the SFJ and reduce the incidence of PE. The two types of surgical treatment were ligation of the GSV at the SFJ or ligation in combination with stripping of the phlebitic vein. Medical therapy consisted of initial intravenous heparin followed by warfarin therapy for a duration varying between 6 weeks and 6 months. The authors offered no definitive conclusions due to reporting of varied outcomes, different follow-up criteria and the retrospective nature of the studies. The differences between the surgical and medical groups were small. The review concludes that medical management with anticoagulants is superior for minimizing complications and preventing subsequent DVT and PE development as compared to surgical treatment with ligation of the GSV at the SFJ or ligation and stripping.

Chandler et al. (2000) conducted a prospective, comparative study to evaluate the effect of extended SFJ ligation when the GSV has been eliminated from participating in thigh reflux by means of endovenous obliteration. Sixty limbs treated with SFJ ligation, and 120 limbs treated without high ligation were selected from an ongoing, multicenter, endovenous obliteration trial on the basis of their having primary varicose veins, GSV reflux, and early treatment dates. Five (8%) high-ligation limbs and seven (6%) limbs without high ligation with patent veins at 6 weeks or less were excluded as unsuccessful obliterations. Treatment significantly reduced symptoms and CEAP clinical class in both groups (P =.0001). Recurrent reflux developed in one (2%) of 49 high-ligation limbs and eight (8%) of 97 limbs without high ligation by 6 months (P =.273). New instances of reflux did not appear thereafter in 57 limbs followed to 12 months. Recurrent varicose veins occurred in three high-ligation
these findings largely inconclusive. Additionally, the authors noted all the trials had some risk of bias concerns. The authors
while non-saphenous reflux is uncommon. Most limbs have signs and symptoms of CVD class 2 and 15% belong in classes 3
and 4.

Labropoulos et al. (1999) studied the distribution and extent of non-truncal superficial venous reflux and its association with the
signs and symptoms of chronic venous disease (CVD) in eighty-four limbs in 62 patients with signs and symptoms of CVD and
evidence of reflux on continuous-wave Doppler. Incompetent superficial vein tributaries were imaged throughout their extent
and both ends were identified. Limbs with reflux in the main trunk of the saphenous veins or the deep, perforator or muscular
veins, superficial or deep vein thrombosis, injection sclerotherapy, varicose-vein surgery, arterial disease and inflammation of
non-venous origin were excluded from the study. The authors observed that this data indicate that reflux confined to superficial
tributaries is found throughout the lower limb. Because this reflux is present without greater and lesser saphenous trunk,
perforator and deep-vein incompetence or proximal obstruction, it shows that reflux can develop in any vein without an
apparent feeding source. Greater saphenous tributaries are affected significantly more often than those of lesser saphenous,
while non-saphenous reflux is uncommon. Most limbs have signs and symptoms of CVD class 2 and 15% belong in classes 3
and 4.

Endovenous Mechanochemical Ablation
Evidence in peer review literature evaluating endovenous mechanochemical ablation for the treatment of venous insufficiency
and varicose veins is limited. Future robust RCTs are warranted along with long-term outcomes to establish the safety and
efficacy of this procedure.

Mohamed et al. (2021) conducted a single-center RCT to compare the technical, clinical and QOL outcomes after EVLA and
MOCA. One hundred fifty patients with symptomatic, unilateral, single-axis superficial venous incompetence (SVI) were
randomized equally to either EVLA or MOCA, both with concomitant phlebectomy when necessary. Primary outcomes were
intraprocedural axial ablation pain scores and anatomical occlusion at 1 year. Secondary outcomes included postprocedural
pain, VCSS, QoL (Aberdeen Varicose Veins Questionnaire (AVVQ) and EuroQol 5-domain utility index), patient satisfaction and
complication rates. Both groups reported low intraprocedural pain scores; on a 100 mm visual analog scale, pain during axial
EVLA was 22 (9-44) compared to 15 (9-29) during MOCA. At 1-year, duplex derived anatomical occlusion rates after EVLA were
63/69 (91%) compared to 53/69 (77%) in the MOCA group (p=0.02). Both groups experienced improvement in VCSS and
AVVQ after treatment, without a significant difference between groups. Median VCSS improved from 6 (5-8) to 0 (0-1) at one
year. Median AVVQ improved from 13.8 (10.0-17.7) to 2.0 (0.0-4.9). One patient in the MOCA group experienced DVT. The
authors concluded EVLA resulted in a higher technical success rate compared to MCOA but clinically, both treatments were
highly efficacious in treating SVI. Patients improved in terms of symptoms, disease severity and QOL. Both procedures resulted
in low procedural pain with a short recovery time. EVLA had higher axial occlusion rates. The authors noted that higher
recanalization rates after MOCA may lead to higher rates of recurrence and long-term follow-up is needed. Long-term follow up
at 5 and 10 years is planned for this study. Limitations include short term follow up and single-center focus.

In an updated Cochrane review, Whing et al. (2021) compared interventions for treating varicosities of the GSV. The review
included 24 RCTs with 5135 participants who underwent EVLA, RFA, EVSA, UGFS, cyanoacrylate glue, MOCA, or high ligation
and stripping. The authors found there was no clear difference in technical success or recurrence between RFA compared to
MCOA, however, long-term data were not available, and the confidence intervals of the combined data were broad, making
these findings largely inconclusive. Additionally, the authors noted all the trials had some risk of bias concerns. The authors
determined there were a relatively small number of studies for comparison and differences in outcome definitions and time
points reported limited their conclusions. Future studies which provide more evidence on the breadth of treatments are
recommended by the authors. Bootun et al. (2016), Lane et al. (2017), Holewijn et al. (2019), Vähäaho et al. (2019), which were
previously cited in this policy, are included in this review.

Kim et al. (2017) evaluated in a case series whether early efficacy in endovenous MOCA is maintained at 24 months. Patients
with reflux in the GSV involving the sapheno-femoral junction and no previous venous interventions were included. The
occlusion rate of treated veins was assessed with duplex ultrasound. Patient clinical improvement was assessed by CEAP class
and VCSS. Of the initial 126 patients, there were 65 patients with 24-month follow-up. Of these 65 patients, 70% were female,
with a mean age of 70 ± 14 years and an average BMI of 30.5 ± 6. The mean GSV diameter in the upper thigh was 7.6 mm and
the mean treatment length was 39 cm. Adjunctive treatment of the varicosities was performed in 14% of patients during the procedure. Closure rates were 100% at one week, 98% at three months, 95% at 12 months, and 92% at 24 months. There was one patient with complete and four with partial recanalization ranging from 7 to 12 cm (mean length 9 cm). There was significant improvement in CEAP and VCSS (P < .001) for all time intervals. Early high occlusion rate with MOCA is associated with significant clinical improvement, which was maintained at 24 months. According to the authors, this finding is suggestive of a good option for the treatment of GSV incompetence. Longer-term outcomes are needed to evaluate MOCA’s efficacy. The study is limited by lack of comparison group and large loss to follow-up.

Vos et al. (2017) conducted a systematic review and meta-analysis to evaluate the efficacy of MOCA) and cyanoacrylate vein ablation (CAVA) for GSV incompetence. Eligible articles were prospective studies that included patients treated for GSV incompetence and described the primary outcome. Exclusion criteria were full text not available, case reports, retrospective studies, small series (n < 10), reviews, abstracts, animal studies, studies of SSV incompetence, and recurrent GSV incompetence. Primary outcome was anatomic success. Secondary outcomes were initial technical success, VCSS, AVVQ score, and complications. Fifteen articles met the inclusion criteria. Pooled anatomic success for MOCA and CAVA was 94.7% and 94.8% at 6 months and 94.1% and 89.0% at 1 year, respectively. VCSS and AVVQ score significantly improved after treatment with MOCA and CAVA. The authors conclude that both of these non-thermal techniques are promising that could serve as alternatives for thermal ablation techniques. However, to determine their exact role in clinical practice, high-quality RCTs comparing these novel modalities with well-established techniques are required. This study is limited by inclusion or mostly uncontrolled studies to assess the efficacy and safety of MOCA. Elias and Raines (2012) and Bishawi et al. (2014), which were previously cited in this policy, are included in the Vos et al. (2017) meta-analysis.

Witte et al. (2017a) conducted a systematic review and meta-analysis of MOCA of saphenous veins using the ClariVein to report on the anatomical, technical, and clinical success. The literature search identified 759 records, of which 13 were included, describing 10 unique cohorts. A total of 1521 veins (1267 GSV and 254SSV) were included, with cohort sizes ranging from 30 to 570 veins. The pooled anatomical success rate after short-term follow up was 92% (95% CI 90-94%) (n = 1314 veins). After 6 and 12 months these numbers were 92% (95% CI 88-95%) (n = 284) and 91% (95% CI 86-94%) (n = 228), respectively. The long-term anatomical success rates at 2 and 3 years were 91% (95% CI 85-95%) (n = 136) and 87% (95% CI 75-94%) (n = 48), respectively. Major complications and especially nerve injury were very rare (≤ 0.2%). All studies were of moderate or good quality using the methodological index for non-randomized studies (MINORS) scoring scale. The authors concluded that MOCA using the ClariVein in combination with liquid sclerosant is associated with an anatomical success rate ranging from 87% to 92% and good clinical success. However, they reported that no RCTs are available studying the anatomical success after MOCA compared to the endothermal ablation.

Witte et al. (2017b) reported midterm results of MOCA for treating GSV insufficiency. In a 1-year period, 85 consecutive patients undergoing MOCA with polidocanol in 104 limbs were enrolled in a prospective registry. The patients were evaluated at baseline and during follow-up (4 weeks and 1, 2, and 3 years) using duplex ultrasound, the CEAP classification, the VCSS, the RAND Short Form 36-Item Health Survey (RAND-SF36), and the AVVQ. Primary outcome measures were clinical and anatomic success. Secondary outcome measures included general and disease-specific QoL and re-interventions. After a median follow-up of 36 months (interquartile range 12.5, 46.3), recanalization occurred in 15 (15%) of 102 successfully treated vein segments. Anatomic success was 92%, 90%, and 87% after 1, 2, and 3 years, respectively. The VCSS improved at all time intervals compared to the preprocedural median. The clinical success at 3 years was 83%. The AVVQ and RAND-SF36 scores showed an improvement at all time intervals compared to baseline values. Between 12 and 36 months, however, a significant deterioration was observed in VCSS, which was accompanied by worsening of disease-specific and general QoL. Although the authors concluded that MOCA demonstrated to be an effective treatment modality for GSV insufficiency at midterm follow-up, clinical results seemed to drop over time. Additionally, these findings are limited by lack of comparison group undergoing a different treatment.

Vun et al. (2015) assessed the efficacy of the ClariVein system for the treatment of superficial vein incompetence. Fifty-one GSVs and six SSVs were treated. Duplex showed a technical success rate of 91%. Comparison with 50 RFA and 40 EVLA procedures showed procedure times were significantly less for ClariVein than for either RFA or EVLA. Median pain scores were significantly lower for ClariVein than for RFA and EVLA. No major complications or deep vein thromboses were reported. Study limitations included small sample size, lack of randomization and short-term follow-up. Further data on long-term clinical outcomes is needed.
In a prospective case series, Boersma et al. (2013) evaluated the feasibility, safety and 1-year results of MOCA of SSV incompetence. Fifty consecutive patients were treated using the ClariVein device and polidocanol. At the 6-week assessment, all treated veins were occluded. One-year follow-up showed a 94% anatomic success rate and no major complications. The authors concluded that MOCA is a safe, feasible and efficacious technique for treating SSV incompetence. This study is limited by lack of control group, small sample size and short-term follow-up.

In a prospective comparison study, van Eekeren et al. (2013) evaluated postoperative pain and QoL after RFA and MOCA for GSV incompetence. Sixty-eight patients with unilateral GSV incompetence were included. Patients treated with MOCA reported significantly less postoperative pain than patients treated with RFA during the first 14 days after treatment. The lower postoperative pain score was associated with a significantly earlier return to normal activities and work. At 6 weeks, patients in both groups perceived an improved change in health status and an improved disease-specific QoL. This study is limited by lack of randomization, small sample size and short-term follow-up.

In a pilot study, van Eekeren et al. (2011) evaluated the feasibility and safety of endovenous MOCA for the treatment of GSV incompetence. Thirty limbs in 25 patients (18 women; mean age 52 years) with GSV incompetence were treated with the ClariVein® device. Initial technical success, complications, patient satisfaction and classification by VCSS) were assessed 6 weeks after the treatment. Initial technical success of MOCA was 100%. There were no major adverse events. Duplex ultrasonography at 6 weeks showed 26 (87%) of 30 veins were completely occluded. Three veins showed partial recanalization in the proximal and distal GSV. One patient had full segment recanalization and was successfully retreated. The VCSS significantly improved at 6 weeks. Patient satisfaction was high, with a median satisfaction of 8.8 on a 0-10 scale. The authors concluded that endovenous MOCA is feasible and safe in the treatment of GSV incompetence. Larger studies with a prolonged follow-up are indicated to prove the efficacy of this technique. This study is limited by lack of comparison group undergoing a different treatment approach.

**Endovascular Embolization with Cyanoacrylate-Based Adhesive**

Quality evidence in peer review literature evaluating endovascular embolization with cyanoacrylate-based adhesive for the treatment of venous insufficiency and varicose veins is limited. Future robust RCTs are warranted along with long-term outcomes to establish the safety and efficacy of this procedure. An ongoing RCT may provide more definitive findings about this technology (NCT03820947).

An ECRI clinical evidence assessment (2021) suggests that VenaSeal is safe and as effective as RFA for treating varicose veins in patients with venous reflux disease. However, how well VenaSeal works compared with other treatment modalities cannot be determined because the SR assessed too few patients for each comparison and no studies in the SR performed head-to-head comparisons. The report determined the evidence was somewhat favorable but RCTs are needed to compare VenaSeal with other treatment modalities. Limitations of the reviewed studies include risk for lack of blinding, single-center focus, and lack of randomization.

A Hayes report, Cyanoacrylate Embolization (VenaSeal Closure System) for the Treatment of Varicose Veins, evaluated 7 clinical studies on the efficacy and safety of cyanoacrylate embolization with the VenaSeal Closure System. The evidence included 1 randomized controlled trial, 1 cohort study, 1 case series and 4 pre-post studies. The conclusion states that this approach has potential but unproven benefits and that a low-quality body of evidence suggests that the VenaSeal Closure System may result in reduced symptom severity, improved QoL and similar occlusion rates when compared with RFA however, substantial uncertainty remains regarding its effectiveness due to the lack of well-designed comparative studies (2020, updated 2021).

The VenaSeal Sapheon Closure System Pivotal Study (VeClose) is a multi-center RCT that compared cyanoacrylate closure (CAC) to RFA for the treatment of incompetent great saphenous veins. In this trial, 222 subjects with symptomatic GSV incompetence were randomly assigned to receive either CAC (n=108) with the VenaSeal Sapheon Closure System or RFA (n=114). The primary endpoint was closure of the target vein at month 3, as assessed by duplex ultrasound. To determine non-inferiority of CAE to RFA, the investigators used a predetermined margin of 10%. Secondary endpoints included subject-rated pain experienced during the procedure (i.e., pain experienced after vein access but before all treatment/access catheters were removed), investigator-rated ecchymosis at day 3, adverse events, and details of adjunctive procedures. Patient follow-up visits were on day 3 and at months 1, 3, 6, 12, 24, and 36. For the extension study, patients who were successfully contacted and were interested in participation provided written informed consent for the 60-month follow-up visit. Assessments tools included the VCSS, AVVQ and EuroQol-Five Dimension (EQ-5D) quality of life survey. This trial has generated multiple publications that
reported outcomes with various follow-up periods e.g., 3 months (Morrison, 2015), 12 months (Morrison, 2017) 24 months (Gibson, 2018a) 36 months (Morrison, 2019), and 60 months (Morrison, 2020), as well as a publication with results of a roll-in phase analysis, which included 20 additional patients treated with CAC (Kolluri, 2016). Design limitations of this study and the resulting publications included lack of blinding of the subjects or assessors to the intervention. Furthermore, the primary endpoint of the study was complete closure of the target vein at 3 months after index treatment, thus the study may not have been powered to detect clinically significant differences between treatments groups for important outcomes and at different times of follow-up. These studies were also included in the Hayes report (2020; updated 2021). The individual studies are listed below:

- Morrison et al. (2015) reported 3-month outcomes from the VeClose trial. No adjunctive procedures such as phlebectomy and UGFS were allowed until after the month 3 visit. The closure rates were 99% for VenaSeal and 96% for RFA. Pain experienced during the procedure was reported as mild and was similar between treatment groups. Good safety profiles were reported with both treatments. The authors concluded that cyanoacrylate ablation did not require tumescent anesthesia, was associated with less post procedure ecchymosis, and was noninferior to RFA for the treatment of incompetent GSVs at month 3 after the procedure.
- Morrison et al. (2017) reported 12-month outcomes from the VeClose trial. Of 222 randomized patients, a 12-month follow-up was obtained for 192 (95 CAC and 97 RFA; total follow-up rate, 86.5%). The complete occlusion rate was nearly identical in both groups (97.2% in the CAC group and 97.0% in the RFA group). Twelve-month freedom from recanalization was similar in the CAC and RFA groups, although there was a trend toward greater freedom from recanalization in the CAC group (P = .08). The authors reported that patient symptoms and QoL improved equally in both groups.
- Twenty-four-month outcomes from the VeClose trial were reported by Gibson et al (2018a). One hundred and seventy-one patients completed the 24-month follow-up, which included 87 from the CAC group and 84 from the RFA group. The 24-month GSV closure rate was 95.3% in the CAC group and 94.0% in the RFA group. Symptoms and QoL improved similarly in both groups. No clinically significant device- or procedure-related late adverse events were reported. The authors concluded that both CAC and RFA were effective in closure of the target GSV, resulting in similar and significant improvements in the patient's QoL through 24 months.
- One hundred and forty-six patients completed the 36-month follow-up to the VeClose trial, which included 72 patients from the CAC group and 74 patients from the RFA group, with outcomes reported by Morrison et al. (2019). The 36-month GSV closure rate was 94.4% for the CAC group and 91.9% for the RFA group. Stable improvement in symptoms and QoL was observed in both groups. Adverse event rates between the 24- and 36-month visits were similar between the groups as were serious adverse events which were infrequent and judged unrelated to either the device or the procedure in both groups. The authors surmised the results of this trial continue to demonstrate the safety and efficacy of CAC for the treatment of GSV incompetence with vein closure rate at 36 months similar to that of RFA. The findings are limited by the loss to follow up (34%), which could have introduced biases in the findings.
- Morrison et. al. (2020) reported 60-month outcomes from the VeClose trial with a total of 89 patients in the original study completing the 60-month visit. Of those, 47 patients were from the CAC group, 33 patients were from the RFA group, and 9 patients were from the roll-in CAC group. No new recanalization events were observed between 36 and 60 months of follow-up. Kaplan-Meier estimates for freedom from recanalization in the randomized CAC and RFA groups were 91.4% and 85.2%, respectively. Both groups demonstrated sustained improvements in EuroQol-5 Dimension (EQ-5D) and QoL. Whereas patients assigned to C0 or C1 clinical class were excluded from the original study, more than half of all returning patients (64% [57/89]) were now assigned to C0 or C1, suggesting an improved clinical class from baseline. Furthermore, 41.1% of returning CAC patients and 39.4% of returning RFA patients at least two CEAP clinical classes lower than at baseline. The authors concluded that CAC and RFA were effective in achieving complete target vein closure of the GSV at long-term follow-up. CAC was also associated with sustained improvements in symptoms and QoL, lower CEAP class, and high level of patient satisfaction without serious adverse effects between 36 and 60 months. The limitations of this publication included the small rate of successful follow up i.e., 36% of the original study randomized population, which could have introduced biases in the findings.

Eroglu and Yasim (2018) conducted an RCT to compare early and two-year results for N-butyl cyanoacrylate (NBCA) using the VariClose Vein Sealing System (Biolas, FG Grup, Turkey), RFA, and EVLA in the treatment of varicose veins. The primary endpoint was the occlusion rate, and secondary endpoints were incidence of complications, and patient satisfaction, including freedom from pain during and after the procedure, complications observed, time to return-to-work and change in VCSS scores. A total of 525 patients were randomized (175 patients in each treatment arm) and 456 patients (NBCA, n=168; RFA, n=149; and EVLA, n=139) had evaluable results i.e., post-procedural ultrasounds and assessments completed at 2 days, and 6, 12 and 24 months. Occlusion rates were similar at 6, 12, and 24 months (6 months [NBCA 98.1%, RFA 94.1%, and EVLA 95.1%, p=0.14], 1 year [NBCA 94.7%, RFA 92.5%, and EVLA 94.2%, p=0.72], 2 years [NBCA 92.6%, RFA 90.9%, and EVLA 91.5%, p=0.89]). Peri-
procedural pain was significantly lower after NBCA (p<0.001) but complication rates (DVT, bleeding, and phlebitis) were similar. Time to return-to-work was shortest after NBCA (NBCA 1.04 days, RFA 1.56 days and EVLA 1.31 days (p<0.001) with 95% (NBCA), 50% (RFA) and 75% (EVLA) of patients returning to work on Day 1. Pre-procedural VCSSs were the same in all groups. A decrease was observed in VCSS values in all groups at 6 months, and this persisted at 1 and 2 years. However, VCSS scores at 6 months and 2 years were significantly lower in the NBCA group (p<0.001). Foam sclerotherapy was subsequently applied to varicose tributaries in 18 patients from all groups. The authors concluded that no differences were observed in occlusion rates between the three modalities, but NBCA appeared superior with respect to peri-procedural pain, return-to-work and decreased VCSS. Limitations of this study include that the individuals who performed the procedures were also those who completed the evaluations, the number of patients lost to follow-up varied between the treatment arms, and the short follow-up period. Additional multi-center randomized trials with longer follow-up are needed to further evaluate NBCA in the treatment of varicose veins. Currently, the VariClose Vein Sealing System (Biolas, FG Grup, Turkey) is under research in countries other than the United States and has neither been approved nor cleared for marketing by the FDA.

Gibson et al. (2018b) reported three-month outcomes from a post-market case series study of endovenous cyanoacrylate closure by the VenaSeal system (the WAVES study). Fifty subjects with symptomatic GSV, SSV, and/or accessory saphenous vein incompetence were treated with the VenaSeal system with no post procedure compression stockings. Concomitant procedures were not allowed as part of the original study protocol. Treating physicians predicted the type and nature of any concomitant procedures that they would usually perform at the time of ablation, if not limited by the constraints of the study. Evaluations were performed at one week, one and three months and included duplex ultrasound, numeric pain rating scale, revised VCSS, the AVVQ, and time to return to work and normal activities. At the three-month visit, the need for and type of adjunctive procedures were recorded. Complete closure at three months was achieved in 70 (99%) of the treated veins (48 GSVs, 14 accessory saphenous veins, eight SSV s). Revised VCSS improved from 6.4 ± 2.2 to 1.8 ± 1.5 (P < .001) and AVVQ from 17.3 ± 7.9 to 6.5 ± 7.2 (P < .0001). Sixty-six percent of patients underwent tributary treatment at three months. The percentage of patients who required adjunctive treatments at three months was lower than had been predicted by the treating physicians (65% versus 96%, p=.0002). The authors reported that closure rates were high in the absence of the use of compression stockings or side branch treatment. Improvement in QoL was significant, and the need for and extent of concomitant procedures was significantly less than had been predicted by the treating physicians. Additional studies with larger patient populations are needed to further evaluate the need for concomitant procedures with the VenaSeal system. These findings are limited by lack of comparison group undergoing a different treatment. This study was also included in the Hayes report (2020).

Gibson and Ferris (2017b) reported results of a prospective case series study (the WAVES study) of cyanoacrylate closure for the treatment of GSVs, SSVs, and/or accessory saphenous veins up to 20 mm in diameter (n=50). Compression stockings post-procedure were not utilized. Patients returned at 1 week and 1 month for follow-up. All treated veins (48 GSV, 14 accessory saphenous veins, and 8 SSVs) had complete closure by duplex ultrasound at seven days and one month. Mean time to return to work and normal activities was 0.2 ± 1.1 and 2.4 ± 4.1 days, respectively. The revised VCSS was improved to 1.8 ± 1.4 (p < .001) and AVVQ score to 8.9 ± 6.6 (p < .001) at one month. Phlebitis in the treatment area or side branches occurred in 10 subjects (20%) and completely resolved in all but one subject (2%) by one month. The authors concluded that cyanoacrylate closure is safe and effective for the treatment of one or more incompetent saphenous or accessory saphenous veins, closure rates were high even in the absence of the use of compression stockings or side branch treatment. Time back to work or normal activities was short and improvements in venous severity scores and QOL were in the authors’ opinion significant, comparing favorably with alternative treatment methods. RCTs with a larger patient population and longer follow-up periods are needed to validate findings. The findings of this study are limited by lack of comparison group undergoing a different treatment approach. This study was also included in the Hayes report (2020).

Bozkurt and Yilmaz (2016) conducted a prospective comparative study of 310 adult subjects who were treated with cyanoacrylate ablation or endovenous laser ablation. The primary endpoint of this study was complete occlusion of the GSV. One, three-, and 12-months closure rates were 87.1, 91.7, and 92.2% for EVLA and 96.7, 96.6, and 95.8% for cyanoacrylate ablation groups. Closure rate at first month was significantly better in cyanoacrylate ablation group (<0.001). Although there is a trend of better closure rates in cyanoacrylate ablation patients, this difference did not reach to the statistical difference at sixth and 12th month (p = 0.127 and 0.138, respectively). The authors concluded that the efficacy and safety analysis show that cyanoacrylate ablation is a safe, simple method which can be recommended as an effective endovenous ablation technique. However, follow-up data of greater than one year is needed to clarify the future role of cyanoacrylate ablation for the treatment incompetent GSVs. This study was also included in the Hayes report (2019).
Almeida et al. (2015) evaluated the safety and effectiveness of endovenous cyanoacrylate-based embolization of incompetent GSVs in a case series study of 38 patients. At 12 months, 36 patients were available for follow-up and 24 patients at 24 months. Complete occlusion of the treated GSV was confirmed by duplex ultrasound in all patients except for one complete and two partial recanalization’s observed at, 1, 3 and 6 months of follow-up, respectively. Kaplan-Meier analysis yielded an occlusion rate of 92.0% (95% CI 0.836-1.0) at 24 months follow-up. VCSS improved in all patients from a mean of 6.1 ± 2.7 at baseline to 1.3 ± 1.1, 1.5 ± 1.4 and 2.7 ± 2.5 at 6, 12 and 24 months, respectively (p < .0001). Edema improved in 89% of legs (n = 34) at 48 hours follow-up. At baseline, only 13% were free from pain. At 6, 12 and 24 months, 84%, 78% and 64% were free from leg pain, respectively. Small sample size and lack of comparison groups are limitations to this study. This study was also included in the Hayes report (2019).

A prospective multicenter case series study was conducted on 78 patients with GSV reflux using cyanoacrylate embolization (Proebstle et al., 2015). Clinical examination, QoL assessment and duplex ultrasound were performed at 2 days, 1, 3, 6, and 12 months. 68 (97.1%) were available for 12-month follow-up. Two-day follow-up showed one proximal and one distal partial recanalization. Three additional proximal recanalization’s were observed at 3-month (n = 2) and 6-month (n = 1) follow-up. Cumulative 12-month survival free from recanalization was 92.9% (95% confidence interval, 87.0%-99.1%). Mean (standard deviation) Venous Clinical Severity Score improved from 4.3 ± 2.3 at baseline to 1.1 ± 1.3 at 12 months. AVVQ score showed an improvement from 16.3 at baseline to 6.7 at 12 months (P < .0001). Side effects were generally mild; a phlebitic reaction occurred in eight cases (11.4%) with a median duration of 6.5 days (range, 2-12 days). Pain without a phlebitic reaction was observed in five patients (8.6%) for a median duration of 1 day (range, 0-12 days). No serious adverse event occurred. Paresthesia was not observed. The authors concluded that endovenous CA embolization of refluxing GSVs is safe and effective without the use of tumescent anesthesia or compression stockings. Additional studies are needed to validate the effectiveness of cyanoacrylate embolization. This study was also included in the Hayes report (2020).

**Endovenous Foam Sclerotherapy**

Evidence in peer review literature evaluating endovenous foam sclerotherapy for the treatment of truncal superficial veins in the lower extremities is limited and does not support a benefit compared to established therapies. Future robust RCTs are warranted along with long-term outcomes to establish the safety and efficacy of this procedure.

In an updated Cochrane review, Whing et al. (2021) compared interventions for treating varicosities of the GSV. The review included 24 RCTs with 5135 participants who underwent EVLA, RFA, EVSA, UGFS, cyanoacrylate glue, MOCA, or high ligation and stripping. The review compared EVLA and UGFS and found technical success may be better in EVLA patients up to 5 years and over five years. Recurrence rates had no clear difference up to 3 years and at five years. The authors state there were a relatively small number of studies for comparison and differences in outcome definitions and time points reported limited their conclusions. Future studies which provide more evidence on the breadth of treatments are recommended by the authors. Lawaetz et al. (2017) and Vähäaho et al. (2018), which were previously cited in this policy, are included in this review.

In an ECRI Clinical Evidence Assessment (2020), Varithena injectable foam was found to improve symptoms and appearance of varicose veins when compared to placebo or other unspecified sclerotherapy agents. Evidence was based on three double-blind and one open-label, multicenter, RCTs. A small open-label extension of one of the RCTs found Varithena’s beneficial effects were sustained at 1-year follow-up. A separate cohort study found patients had better vein occlusion rates with high ligation surgery than with Varithena at 1-year follow-up. Adverse effects included pain, thrombophlebitis, bruising and thrombus in nontarget vessels and were considered minor. The report notes that longer-term, independent RCTs would be useful to confirm results and to compare Varithena with other varicose vein treatments because no data were available on RFA or laser therapy.

A Hayes Health Technology Assessment (2019) researched 6 clinical studies (n=77-399) that evaluated the efficacy or safety of polidocanol endovenous microfoam (PEM) 1% in treating varicose veins. Eligible studies included five RCTs and one case series. The patients included in the studies had SFJ, GSV or SSV incompetence. The assessment concluded there was a low-quality body of evidence that suggested PEM 1% may provide relief of symptoms and result in occlusion and elimination of reflux. The authors concluded that this approach has potential but unproven benefit. Additionally, substantial uncertainty remains regarding the effectiveness of PEM 1% in relation to other sclerosants and other surgical approaches. The report recommended more well-designed, independent RCTs to further establish the comparative safety and effectiveness of PEM 1%, identify optimal patient selection, and determine the durability of its beneficial effects. (Hayes, 2019; updated 2021).
Gibson et al. (2017a) conducted a randomized, placebo-controlled, multicenter study to evaluate the safety and efficacy of PEM (1%, Varithena [polidocanol injectable foam]). Patients (n = 77) with symptomatic, visible varicose veins were randomized to treatment with either Varithena 1% or placebo. Patients were assessed at baseline and weeks 1, 4, 8, and 12 post-treatment. The data showed that Varithena provided greater mean changes from baseline in patient-reported assessments of symptoms (e.g., heaviness, aching, swelling, throbbing, itching [HASTI]) score 30.7 points vs 16.7 points, \( p = 0.0009 \), primary endpoint; and modified Venous Insufficiency Epidemiological and Economic Study-Quality-of-Life/Symptoms (m-VEINES-QOL/Sym; \( p < 0.001 \)), physician-assessed VCSS, and physician- and patient-assessed appearance compared with placebo. The HASTI score correlated highly with the modified-VEINES-QOL/Sym and Chronic Venous Insufficiency Questionnaire-2 scores (\( r = 0.7 \) to > 0.9, \( p < 0.001 \)). Adverse events included contusion, incision-site hematoma, and limb discomfort. Venous thrombus adverse events were reported as mild and generally resolved without sequelae. Large RCTs with longer-term outcomes and comparisons to established treatments for varicose veins are needed to evaluate the clinical utility of this procedure. The findings of this study are limited by the short follow up and lack of comparison with an established therapy.

Lal et al. (2017) evaluated the relationship between patient-reported symptoms and functional and psychological impact of varicose veins following treatment with PEM1%. Data were pooled from two randomized trials on varicose vein treatment. In 221 patients (109 PEM 1%; 112 placebo), PEM 1% was associated with median improvements of 2.5 points and 4.0 points on the m-VEINES-QOL/Sym functional limitations and m-VEINES-QOL/Sym psychological limitations scores, compared to 0 and 1.0 point. Cumulative distribution function curves revealed that 20-30% more patients in the PEM 1% group achieved clinically meaningful functional and psychological improvement versus placebo group. Patients with above-average symptom improvement had better functional and psychological improvement. PEM 1% treatment had higher odds of clinically meaningful functional and psychological improvement. Length of post-procedure follow-up was not provided. Furthermore, this study did not compare endovenous microfoam to established treatment for varicose veins.

In a multicenter, randomized, placebo-controlled, blinded study in patients with GSV incompetence and symptomatic and visible superficial venous disease, Vasquez et al. (2017) evaluated the efficacy and safety of PEM 0.5%, 1.0%, or placebo each administered with endovenous thermal ablation. Co-primary endpoints were physician-assessed and patient-assessed appearance change from baseline to week 8. A total of 117 patients received treatment (38 placebo, 39 PEM 0.5%, 40 PEM 1%). Physician-rated vein appearance at week 8 was significantly better with PEM (\( p = 0.001 \) vs. placebo); patient-assessed appearance trended similarly. In the authors’ opinion, PEM provided improvements in clinically meaningful change in patient-assessed and physician-assessed appearance (\( p < 0.05 \)), need for additional treatment (\( p < 0.05 \)), SFJ reflux elimination, symptoms, and QOL. In PEM recipients, the most frequent adverse event was superficial thrombophlebitis (35.4%). While these results appear promising, PEM outcomes were compared with placebo and with a short follow-up period. Additional RCTs comparing PEM outcomes with other established varicose vein treatment outcomes, and with a longer follow-up period are needed.

King et al. (2015) reported a multicenter, parallel group study (VANISH-1), to determine if a single administration of \( \leq 15 \) mL of pharmaceutical-grade PEM (Varithena [polidocanol injectable foam]) could alleviate symptoms and improve appearance of varicose veins in a typical population of patients with moderate to very severe symptoms of superficial venous incompetence and visible varicocities of the GSV system. The primary endpoint was patient-reported venous symptom improvement measured by change from baseline to week 8 in 7-day average VVSymQ score. Patients (n=279) were randomized to five groups: PEM 0.125% (control), 0.5%, 1%, 2%, or placebo. At week 8, VVSymQ scores for the pooled PEM group (0.5% + 1% + 2%; \( p < .0001 \)) and individual dose concentrations (\( p < .001 \)) were greater as compared to placebo. Most adverse events were mild and resolved without sequelae. No pulmonary emboli were reported. The authors concluded that this study demonstrated that a single administration of up to 15 mL of PEM is a safe, effective, and convenient treatment for the symptoms of superficial venous incompetence and the appearance of visible varicocities of the GSV system. Doses of 0.5%, 1%, and 2% PEM appear to have an acceptable risk-benefit ratio. Additional studies with comparisons to other varicose vein treatments and over a longer period of time are needed before determining the safety and efficacy of this procedure.

In the VANISH-2 trial, Todd et al. (2014) evaluated the efficacy and safety of PEM in treatment of symptoms and appearance in patients with SFJ incompetence due to reflux of the GSV or major accessory veins. Patients were randomized equally to receive PEM 0.5%, PEM 1.0% or placebo. In 232 treated patients, PEM0.5% and PEM 1.0% were superior to placebo, with a larger improvement in symptoms (VVSymQ (6.01 and-5.06, respectively, versus -2.00; \( P < 0.0001 \)) and greater improvements in physician and patient assessments of appearance (\( P < 0.0001 \)). These findings were supported by the results of duplex ultrasound and other clinical measures. Of the 230 PEM-treated patients (including open-label patients), 60% had an adverse event compared with 39% of placebo; 95% were mild or moderate. The authors concluded that PEM provided clinically
meaningful benefit in treating symptoms and appearance in patients with varicose veins. However, longer-term outcomes with comparisons between PEM and other established treatments for varicose veins are needed to evaluate the clinical utility of this procedure.

**Clinical Practice Guidelines**

**American College of Phlebology**

The American College of Phlebology Guidelines Committee (Gibson et al., 2017c) performed a systematic review of the literature regarding the clinical impact and treatment of incompetent accessory saphenous veins. They developed a consensus opinion that patients with symptomatic incompetence of the accessory great saphenous veins (anterior and posterior accessory saphenous veins) be treated with EVTA (laser or radiofrequency) or UGFS to eliminate symptomatology (Recommendation Grade 1C).

The American College of Phlebology Guidelines Committee (2016) updated their evidence-based recommendations for treatment of superficial venous disease of the lower leg. They recommend that named veins (GSV, SSV, AAGSV, posterior accessory of the great saphenous vein [PAGSV], intersaphenous vein [Vein of Giacomini]) must have a reflux time > 500 msec regardless of the reported vein diameter (Grade 1A).

EVTA (laser and radiofrequency) is the Committee’s preferred treatment for saphenous and accessory saphenous (GSV, SSV, AAGSV, PAGSV) vein incompetence (Grade 1B). They suggest mechanical/chemical ablation may also be used to treat truncal venous reflux (Grade 2B). They further comment that open surgery is appropriate in veins not amenable to endovenous procedures but otherwise is not recommended because of increased pain, convalescent time, and morbidity (Grade 1B).

**European Society for Vascular Surgery (ESVS)**

The ESVS released a clinical practice guideline for management of chronic venous disease (Wittens et al., 2015). The guidelines do not recommend liquid or foam sclerotherapy as the first-choice treatment for chronic venous disease C2-C6 due to saphenous vein incompetence. Per the guideline, this procedure should only be used as primary treatment in selected cases, such as those not eligible for surgery or endovenous ablation, and elderly, frail patients with venous ulcers. Cyanoacrylate glue injection and MOCA are not addressed due to lack of publications. The guidelines note that USGF has been used successfully in the treatment of recurrence, although with lower success rates compared with laser ablation.

**National Institute for Health and Care Excellence (NICE)**

In 2020, the National Institute for Health and Care Excellence (NICE) released an update to their guidance on Cyanoacrylate Glue Occlusion for Varicose Veins. The updated guidance states that current evidence on the safety and efficacy of cyanoacrylate glue occlusion for varicose veins is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit. In addition, the guideline states physicians should: 1) only perform the procedure after appropriate training and experience in the use of venous ultrasound; 2) discuss the available options with the patient before making a decision; and 3) follow their hospital’s policies regarding performing procedures and monitoring results.

In an updated guideline on endovenous MOCA for varicose veins, the National Institute for Health and Care Excellence (NICE) (2016) states that current evidence on the safety and efficacy of endovenous MOCA for varicose veins appears adequate to support the use of this procedure provided that standard arrangements are in place for consent, audit and clinical governance. Clinicians are encouraged to collect longer-term follow-up data.

The National Institute for Health and Care Excellence (NICE) 2013 interventional procedure guidance on UGFS specifies that if symptoms related to varicose veins are severe, the main treatment options include endovenous laser treatment and radiofrequency ablation, and surgery (ligation and stripping of the GSVs or ligation with or without stripping of the SSVs, and phlebectomy). The NICE 2013 clinical guideline on the diagnosis and treatment of varicose veins adds that if endovenous ablation is unsuitable, offer UGFS.
The SVS, AVF, AVLS, and SIR developed the appropriate use criteria (AUC) for chronic lower extremity venous disease using the RAND/UCLA Appropriateness Method incorporating best available evidence with expert opinion and engaging a panel of experts in the field through a modified Delphi exercise (Masuda et al. 2020). The consensus does not appear to be based on a systematic review of the literature. One hundred and nineteen scenarios were rated on a scale of one to nine by an expert panel, with one being never appropriate and nine being appropriate. The panelists rated ablation for axial reflux of the GSV, with or without SFJ reflux, in symptomatic patients, CEAP classes 2-6 as appropriate. Per the AUC, when accompanied by no SFJ reflux (the junction is either assumed or proven to be competent or previously interrupted and communicates with the GSV through incompetent thigh perforators or other sources of collateral flow) the remaining refluxing GSV may be the source of recurrent symptoms. Therefore, for axial GSV reflux, ablating the GSV will likely lead to decreased recurrence even if the SFJ shows no reflux. The authors note that the AUC statements were intended to serve as a guide to patient care, particularly in areas where high quality evidence is lacking and was not meant to be a guide that addresses all clinical situations.

The SVS and AVF released joint clinical practice guidelines regarding the care of patients with venous leg ulcers (O’Donnell et al., 2014). For patients with a venous leg ulcer (C6), and incompetent superficial veins that have reflux to the ulcer bed in addition to pathological perforating veins (>500ms reflux duration and diameter of >3.5mm), that are located beneath or associated with the ulcer bed, the guideline recommends ablation of both the incompetent superficial veins and perforator veins in addition to standard compressive therapy to aid in ulcer healing and prevent recurrence. For patients who are at risk for a venous leg ulcer (C4b), or have a healed venous ulcer (C5), and have axial reflux directed to the bed of the affected skin/ulcer, the guidelines recommend ablation of the incompetent superficial veins in addition to standard compressive therapy.

The SVS and AVF released joint clinical practice guidelines regarding the care of patients with varicose veins (Gloviczki et al., 2011). The guidelines state that EVTA is recommended over high ligation and inversion stripping of the saphenous vein to the level of the knee. For treatment of the incompetent saphenous vein, the SVS and AVF recommend EVTA over chemical ablation with foam. The guidelines do not discuss MOCA. The guideline also states that patients who undergo high ligation alone of the GSV have recurrent reflux in the residual GSV which may cause new symptoms and increase the risk of reoperation.

U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Vein ligation surgery is a procedure and therefore not subject to FDA regulation.

The ClariVein® infusion catheter (Vascular Insights) received FDA approval (K071468) on March 20, 2008. The device is designed to introduce physician-specified medicaments into the peripheral vasculature. See the following website for more information: http://www.accessdata.fda.gov/cdrh_docs/pdf7/K071468.pdf. (Accessed December 1, 2021)

The VenaSeal™ Closure System received the FDA's pre-market approval (PMA) on February 20, 2015 (P140018). The device is indicated for the permanent closure of lower extremity superficial truncal veins, such as the great saphenous vein (GSV), through endovascular embolization with coaptation. VenaSeal is intended for use in adults with clinically symptomatic venous reflux as diagnosed by duplex ultrasound (DUS). See the following website for more information: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140018. (Accessed December 1, 2021)

Varithena (polidocanol injectable foam) (Provensis Ltd.) received FDA approval on November 25, 2013 as a sclerosing agent indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein system above and below the knee. See the following websites for more information:

- https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/205098Orig1s000ltr.pdf
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205098s000lbl.pdf

(Accessed December 1, 2021)
References


ECRI. VenaSeal Closure System (Medtronic plc.) for embolizing varicose veins. Plymouth Meeting (PA): ECRI; 2021 Feb 4. (Clinical Evidence Assessment).


Todd KL 3rd, Wright DI, VANISH-2 Investigator Group. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology. 2014 Oct;29(9):608-18.

UnitedHealthcare Insurance Company Generic Certificate of Coverage


**Policy History/Revision Information**

<table>
<thead>
<tr>
<th>Date</th>
<th>Summary of Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/01/2022</td>
<td>Coverage Rationale</td>
</tr>
<tr>
<td></td>
<td>• Removed references to specific InterQual” release dates; refer to the most current InterQual” criteria</td>
</tr>
<tr>
<td></td>
<td>Supporting Information</td>
</tr>
<tr>
<td></td>
<td>• Updated References section to reflect the most current information</td>
</tr>
<tr>
<td></td>
<td>• Archived previous policy version 2022T0447FF</td>
</tr>
</tbody>
</table>

**Instructions for Use**

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

This Medical Policy may also be applied to Medicare Advantage plans in certain instances. In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence (Medicare IOM Pub. No. 100-16, Ch. 4, §90.5).

UnitedHealthcare may also use tools developed by third parties, such as the InterQual™ criteria, to assist us in administering health benefits. UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.